# argenx SE share price today (argenx SE, ARGX)

> argenx SE's results are improving, while its P/E is near the low end of its own history over 1 year, higher than only 9% of past readings. ARGX · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/argx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $894.88 (+4.7% in a year)
- P/E: 31.8× (lower than 91% of the last 1 year)
- Revenue (Sep 2026): $1.8 B (+52.1% on a year ago)
- Profit (Sep 2026): $506 M (+47.0% on a year ago)
- Operating margin: 36.3% (+5.9 points on a year ago)
- ROE: 18%, FY25
- ROIC: 57.0%, against a 4.0% cost of capital: +53.0 points
- Profit that came in as cash: 28%, last 2 years

The main question: profits are rising, but only 28% of the last 2 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the argenx SE share price today? argenx SE's share price was $894.88 at the close on 5 November 2026. It has been rising for 3 weeks. That is 4.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $664 and $1,040, and at that close it sat 61% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. Over the last 9.5 years the share price moved +3,996% while the S&P 500 moved +208%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does argenx SE pay? argenx SE pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is argenx SE on? argenx SE is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is argenx SE profitable? argenx SE earned $506 M of net profit in the Sep 2026 quarter, +47.0% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY25 profit was $1.3 B. That is 28.9% of the quarter's revenue. The same quarter a year earlier earned $344 M. 2 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $1.3 B (+55.1% on the year before). Why profit moved: revenue changed +52.1% on a year earlier and the margin moved +5.9 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +56.0% and revenue +61.7%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does argenx SE make, and is it growing? argenx SE reported $1.8 B of revenue in the Sep 2026 quarter, +52.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 68.3% a year on average. The last full year, FY25, came in at $4.2 B. The last four reported quarters add to $5.9 B. FY25 revenue was $4.2 B, +88.4% on the year before. Recent pace: the last four quarters grew +61.7% on average, against 68.3% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +60.6%, against +76.0% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does argenx SE keep? argenx SE's operating margin was 36.3% in the Sep 2026 quarter, 5.9 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −164.1% and 24.9%. The latest quarter is above every full year in that period. Across 5 years it has been between −164.1% and 24.9%, and FY25's 24.9% is the highest of them. Why the margin moved: operating margin changed +5.9 percentage points on the year while gross margin changed +2.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is argenx SE's profit turning into cash? Over the last 2 years, 28% of argenx SE's reported profit came in as cash from its operations, a gap worth watching. In FY25 it brought in $685 M of operating cash against $1.3 B of profit. After $6.2 M of spending on assets, $679 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does argenx SE's cash go? argenx SE does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $8.8 M on assets over the last 3 years. Averaged over those years that is 0.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $8.8 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is argenx SE's P/E ratio, and how does it compare with its own history? argenx SE's P/E is 31.8×, near the low end of its own history: it has been lower only 9% of the time. Its usual P/E (the middle reading) is 36.5×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +53.1% while the price moved +4.7%. Earnings did better than the price, which pulled the multiple down within its own range. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the argenx SE business getting better or worse? argenx SE's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does argenx SE earn on its capital? argenx SE earned a ROE of 18% in FY25. That is up from a low of −25% in FY22. Its return on capital used (ROIC) is 53.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 30.5% net margin and 0.49× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 30.5% net margin × 0.49× asset turnover × 1.19× leverage (assets divided by equity) ≈ 17.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 57.0% − 4.0% = +53.0 percentage points. The 4.0% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. ## Does argenx SE have too much debt? argenx SE has total debt of $47.0 M against shareholder equity of $8.4 B as of Sep 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.00 in FY21 to 0.01 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the argenx SE shareholding pattern? We have no ownership or short-position figures for argenx SE, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 3.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is argenx SE from balance-sheet trouble? For argenx SE, the Z-score is 19.76. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 19.76 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does argenx SE rank in its industry? 60.8 out of 100, rank 5 of 30 in Biotechnology, with 85% of the evidence available. argenx SE scores 60.8 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 5. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 24.9 + 17.1 + 10.4 + 8.4 = 60.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is argenx SE compared with? argenx SE ranks 5 of 30 Biotechnology companies on the 4-Factor Sector Score, with 60.8 out of 100. 1. [Exelixis, Inc.](https://www.sectoralpha.in/us/stocks/exel) EXEL · breaking out · Most evidence points up · 81% evidence 76.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.7/35 · Revenue 9.3% · Profit 42.8% · Operating margin change 1.9 points · 83% evidence Capital efficiency 20.9/25 · ROCE 46.5% · Operating margin 39.5% · 76% evidence Valuation 14.6/20 · P/E 15.9× · PEG 0.3 · 65% evidence Relative strength 17.9/20 · Lead over its industry 9.7% · Lead over S&P 500 35.4% · 1 year 68.4% · 100% evidence · 8 of 12 weeks ahead Exact sum: 22.7 + 20.9 + 14.6 + 17.9 = 76.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Halozyme Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/halo) HALO · leader · Most evidence points up · 81% evidence 72.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.7/35 · Revenue 41.1% · Profit -25.9% · Operating margin change -2.4 points · 83% evidence Capital efficiency 20.9/25 · ROCE 42.3% · Operating margin 59.8% · 76% evidence Valuation 14.6/20 · P/E 22.4× · PEG 0.25 · 65% evidence Relative strength 18.8/20 · Lead over its industry 21.7% · Lead over S&P 500 48.8% · 1 year 80.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.7 + 20.9 + 14.6 + 18.8 = 72 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Incyte Corporation](https://www.sectoralpha.in/us/stocks/incy) INCY · turning · Most evidence points up · 71% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.1/35 · Revenue 26.9% · Profit 85.3% · Operating margin change 16.3 points · 83% evidence Capital efficiency 20.5/25 · ROCE 28.1% · Operating margin 41.9% · 76% evidence Valuation 10.9/20 · P/E 14× · PEG n/a · 15% evidence Relative strength 7.2/20 · Lead over its industry -12.7% · Lead over S&P 500 8.2% · 1 year 11.4% · 100% evidence · 5 of 12 weeks ahead Exact sum: 27.1 + 20.5 + 10.9 + 7.2 = 65.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Genmab A/S](https://www.sectoralpha.in/us/stocks/gmab) GMAB · leader · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.0/35 · Revenue 18.2% · Profit -39.3% · Operating margin change -3.7 points · 83% evidence Capital efficiency 15.6/25 · ROCE 11.7% · Operating margin 35.2% · 76% evidence Valuation 15.1/20 · P/E 21.4× · PEG 0.21 · 65% evidence Relative strength 19.5/20 · Lead over its industry 33.6% · Lead over S&P 500 65.2% · 1 year 83.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11 + 15.6 + 15.1 + 19.5 = 61.2 · What this means: Relative strength against the index is 65.2%, and revenue and profit growth are weak. 5. argenx SE this page ARGX · turning · Evidence leans up · 85% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.9/35 · Revenue 60.6% · Profit 22.4% · Operating margin change 5.9 points · 95% evidence Capital efficiency 17.1/25 · ROCE 18.9% · Operating margin 36.3% · 76% evidence Valuation 10.4/20 · P/E 32× · PEG 1.39 · 65% evidence Relative strength 8.4/20 · Lead over its industry -17.4% · Lead over S&P 500 2.7% · 1 year 4.7% · 100% evidence · 6 of 12 weeks ahead Exact sum: 24.9 + 17.1 + 10.4 + 8.4 = 60.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [BeOne Medicines AG](https://www.sectoralpha.in/us/stocks/onc) ONC · leader · Evidence leans up · 64% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 34.3% · Profit n/a · Operating margin change 12.4 points · 62% evidence Capital efficiency 13.3/25 · ROCE 13.1% · Operating margin 19.1% · 76% evidence Valuation 9.1/20 · P/E 48.3× · PEG n/a · 15% evidence Relative strength 12.2/20 · Lead over its industry -6.3% · Lead over S&P 500 16.5% · 1 year 21.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23 + 13.3 + 9.1 + 12.2 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Kymera Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/kymr) KYMR · turning · Evidence leans up · 61% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Revenue 100% · Profit n/a · Operating margin change 620.5 points · 62% evidence Capital efficiency 6.8/25 · ROCE -22% · Operating margin -116.3% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 16.9/20 · Lead over its industry 11% · Lead over S&P 500 36.2% · 1 year 118.4% · 100% evidence · 7 of 12 weeks ahead Exact sum: 23.9 + 6.8 + 10 + 16.9 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Spyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/syre) SYRE · quiet · Too little evidence to rank firmly · 56% evidence 56.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue n/a · Profit n/a · Operating margin change 999.3 points · 52% evidence Capital efficiency 8.6/25 · ROCE -24.5% · Operating margin n/a · 61% evidence Valuation 11.0/20 · P/E -8.2× · PEG n/a · 15% evidence Relative strength 12.9/20 · Lead over its industry 21.2% · Lead over S&P 500 46.6% · 1 year 328.9% · 100% evidence · 4 of 12 weeks ahead Exact sum: 23.6 + 8.6 + 11 + 12.9 = 56.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Moderna, Inc.](https://www.sectoralpha.in/us/stocks/mrna) MRNA · leader · Evidence leans up · 64% evidence 55.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.4/35 · Revenue -27.6% · Profit n/a · Operating margin change 80.8 points · 62% evidence Capital efficiency 6.5/25 · ROCE -28.9% · Operating margin -557.9% · 76% evidence Valuation 11.2/20 · P/E -11.6× · PEG n/a · 15% evidence Relative strength 20.0/20 · Lead over its industry 161.6% · Lead over S&P 500 205.6% · 1 year 882.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.4 + 6.5 + 11.2 + 20 = 55.1 · What this means: Relative strength against the index is 205.6%, and revenue and profit growth are weak. 10. [Krystal Biotech, Inc.](https://www.sectoralpha.in/us/stocks/krys) KRYS · quiet · Evidence leans up · 81% evidence 55.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 22.6% · Profit 65.1% · Operating margin change 8 points · 83% evidence Capital efficiency 16.1/25 · ROCE 14.4% · Operating margin 49% · 76% evidence Valuation 12.4/20 · P/E 45.4× · PEG 0.77 · 65% evidence Relative strength 4.1/20 · Lead over its industry -19% · Lead over S&P 500 0.1% · 1 year 51.7% · 100% evidence · 4 of 12 weeks ahead Exact sum: 22.4 + 16.1 + 12.4 + 4.1 = 55 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Jazz Pharmaceuticals plc](https://www.sectoralpha.in/us/stocks/jazz) JAZZ · quiet · Evidence leans up · 74% evidence 55.0 out of 100 Growth Capital Valuation Relative
12. [Royalty Pharma plc](https://www.sectoralpha.in/us/stocks/rprx) RPRX · turning · Evidence leans up · 81% evidence 53.7 out of 100 Growth Capital Valuation Relative
13. [Regeneron Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/regn) REGN · leader · Evidence leans up · 81% evidence 52.8 out of 100 Growth Capital Valuation Relative
14. [Alnylam Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/alny) ALNY · basing · Evidence leans up · 64% evidence 51.6 out of 100 Growth Capital Valuation Relative
15. [Protagonist Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ptgx) PTGX · losing its lead · Evidence leans down · 74% evidence 49.6 out of 100 Growth Capital Valuation Relative
16. [Vertex Pharmaceuticals Incorporated](https://www.sectoralpha.in/us/stocks/vrtx) VRTX · breaking out · Evidence leans down · 85% evidence 46.9 out of 100 Growth Capital Valuation Relative
17. [Bio-Techne Corporation](https://www.sectoralpha.in/us/stocks/tech) TECH · turning · Evidence leans down · 74% evidence 44.4 out of 100 Growth Capital Valuation Relative
18. [Roivant Sciences Ltd.](https://www.sectoralpha.in/us/stocks/roiv) ROIV · turning · Too little evidence to rank firmly · 60% evidence 39.5 out of 100 Growth Capital Valuation Relative
19. [Summit Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/smmt) SMMT · breaking out · Too little evidence to rank firmly · 53% evidence 39.2 out of 100 Growth Capital Valuation Relative
20. [Revolution Medicines, Inc.](https://www.sectoralpha.in/us/stocks/rvmd) RVMD · quiet · Too little evidence to rank firmly · 53% evidence 38.7 out of 100 Growth Capital Valuation Relative
21. [Madrigal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/mdgl) MDGL · quiet · Evidence leans down · 61% evidence 37.2 out of 100 Growth Capital Valuation Relative
22. [Insmed Incorporated](https://www.sectoralpha.in/us/stocks/insm) INSM · basing · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative
23. [BridgeBio Pharma, Inc.](https://www.sectoralpha.in/us/stocks/bbio) BBIO · quiet · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative
24. [BioNTech SE](https://www.sectoralpha.in/us/stocks/bntx) BNTX · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
25. [BioMarin Pharmaceutical Inc.](https://www.sectoralpha.in/us/stocks/bmrn) BMRN · quiet · Most evidence points down · 81% evidence 26.8 out of 100 Growth Capital Valuation Relative
26. [Ascendis Pharma A/S](https://www.sectoralpha.in/us/stocks/asnd) ASND · turning · Too little evidence to rank firmly · 44% evidence 63.3 out of 100 Growth Capital Valuation Relative
27. Apogee Therapeutics, Inc. APGE · Too little evidence to rank firmly · 27% evidence 47.2 out of 100 Growth Capital Valuation Relative
28. Nuvalent, Inc. NUVL · Too little evidence to rank firmly · 20% evidence 41.2 out of 100 Growth Capital Valuation Relative
29. [Crinetics Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/crnx) CRNX · Too little evidence to rank firmly · 35% evidence 38.0 out of 100 Growth Capital Valuation Relative
30. Vaxcyte, Inc. PCVX · breaking out · Too little evidence to rank firmly · 47% evidence 37.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Biotechnology](https://www.sectoralpha.in/us/sectors/biotechnology), all 30 compared on one page. ## Which companies are close to argenx SE in size? argenx SE is the 4th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Vertex Pharmaceuticals Incorporated, Moderna, Inc. and Regeneron Pharmaceuticals, Inc. Just below it: BeOne Medicines AG, Royalty Pharma plc and Revolution Medicines, Inc. ### Biotechnology companies close in size

1. [Vertex Pharmaceuticals Incorporated](https://www.sectoralpha.in/us/stocks/vrtx) $137.6 billion
2. [Moderna, Inc.](https://www.sectoralpha.in/us/stocks/mrna) $96.3 billion
3. [Regeneron Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/regn) $90.6 billion
4. argenx SE $55 billion
5. [BeOne Medicines AG](https://www.sectoralpha.in/us/stocks/onc) $44.1 billion
6. [Royalty Pharma plc](https://www.sectoralpha.in/us/stocks/rprx) $38.8 billion
7. [Revolution Medicines, Inc.](https://www.sectoralpha.in/us/stocks/rvmd) $38.1 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Cheniere Energy, Inc.](https://www.sectoralpha.in/us/stocks/lng) $59.6 billion · Oil & Gas Midstream
2. [Bloom Energy Corporation](https://www.sectoralpha.in/us/stocks/be) $59.3 billion · Electrical Equipment & Parts
3. argenx SE $59.1 billion
4. [Delta Air Lines, Inc.](https://www.sectoralpha.in/us/stocks/dal) $58.4 billion · Airlines
5. [Nu Holdings Ltd.](https://www.sectoralpha.in/us/stocks/nu) $57.9 billion · Banks - Regional

## What else do people ask about argenx SE? ### What were argenx SE's latest quarterly results? argenx SE reported revenue of $1.8 B and net profit of $506 M for the Sep 2026 quarter. Revenue rose 52.1% and profit rose 47.0% compared with a year earlier. Earnings per share were $7.80. The operating margin was 36.3%, 5.9 percentage points higher than a year earlier (as of 5 November 2026). ### What is argenx SE's market cap? argenx SE's market capitalisation is $55.0 B at a stock price of $894.88. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is argenx SE performing? argenx SE's share price has been rising for 3 weeks. In its latest quarter, revenue rose 52.1% and profit rose 47.0% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running (as of 5 November 2026). ### Will argenx SE's stock price go up? This page does not forecast argenx SE's stock price. What it shows instead: the stock price is $894.88, and it has been rising for 3 weeks. Its P/E of 31.8× is higher than 9% of its own last 2 years (as of 5 November 2026). ### Where is argenx SE in its business cycle? argenx SE's FY25 operating margin was 24.9%, against a 5-year range of −164.1% to 24.9%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 36.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the argenx SE story? The main question: profits are rising, but only 28% of the last 2 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is argenx SE a stock worth studying right now? What the numbers show: argenx SE's results are improving, while its P/E is near the low end of its own history over 1 year, higher than only 9% of past readings. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.